Patent · US Active

Combination of vaccination and OX40 agonists

US12178863B2 · kind B2 · utility

0Cited by

99References

14Claims

0Family size

Assignee

CureVac SE · DE

Inventors

Mariola FOTIN-MLECZEK · Sindelfingen, DE
Karl-Josef Kallen · Tübingen, DE
Jan C. Schmollinger · Hersbruck, DE

Key dates

Filing date	Aug 8, 2021
Grant date	Dec 31, 2024
Priority date	—
Expiry date	Jan 23, 2042

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.